Combo Therapy Seen to Enhance Anti-Fibrotic Activity in Lung Cells from IPF Patients in Early Study

Combo Therapy Seen to Enhance Anti-Fibrotic Activity in Lung Cells from IPF Patients in Early Study

A combined treatment, pirfenidone and rapamycin, worked to prevent fibrosis in lung fibroblasts from patients with idiopathic pulmonary fibrosis, new research showed, suggesting a possibly more effective way of treating IPF. 

The study, “Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells” was published in the journal BMC Pulmonary Medicine.

Pirfenidone, marketed as Esbriet by Genentech, is an oral anti-inflammatory and anti-fibrotic drug approved in the U.S. and Europe (among other countries) to treat mild to moderate IPF.

It inhibits collagen synthesis, fibroblast proliferation, fibrosis induced by transforming growth factor β1 (TGF−β), and works to mediate tissue repair. All these activities prevent progression of the fibrotic process and the inflammation associated with it.

The treatment has been shown to prolong survival without disease worsening, slow down the decline in the levels of forced expiratory volume (a measure of lung function), reduce fibrosis and normalize the secretion of pro-inflammatory mediators in IPF patients.

Despite the important contributions that anti-fibrotic drugs such as Esbriet have brought to managing IPF, the ultimate goal is  a treatment that completely halts fibrosis.

With this in mind, researchers investigated if a combined of pirfenidone and rapamycin, another inhibitor of fibroblast proliferation, could improve the effects of pirfenidone alone.

Rapamycin is currently being evaluated in clinical trials as a potential IPF therapy. 

The team studied pirfenidone and rapamycin in lung fibroblasts from IPF patients and human lung epithelial cells grown in the laboratory. Both cell lines were treated with this combination, and in the presence or absence of TGF−β, a major player in fibrosis progression.

The combination significantly inhibited the conversion of fibroblasts into myofibroblasts, an important step in the fibrotic process. But such anti-fibrotic activity was mainly due to the action of pirfenidone.

Since uncontrolled migration of fibroblasts to the injury site is also a main contributor to the formation of scar tissue in the lungs, researchers also investigated the treatment’s effects on this process.

Using  a cell migration assay, they found that both pirfenidone and rapamycin, alone or in combination, reduced the migration of fibroblast cells from IPF patients. Importantly, the slowing of this process was increased by combining pirfenidone with rapamycin, compared with pirfenidone alone.

The combination treatment also inhibited the synthesis of key proteins involved in the fibrotic process, including collagen. Interestingly, each drug inhibited different proteins, indicating that both compounds working together could increase the anti-fibrotic range of action.

Pirfenidone plus rapamycin also did not result in any significant toxicity to the cells.

“These findings indicate that the combination of pirfenidone and rapamycin widen the inhibition range of fibrogenic markers and prevents fibroblast migration,” the researchers concluded. “These findings reveal the importance for a combined therapy that may result in a more efficient treatment.”


  1. Ric Ellens says:

    that could effectively target pathophysiological pathways involved in fibrosis. GPR40 and GPR84 are G protein-coupled receptors with free fatty acid ligands and are associated with metabolic and inflammatory disorders. Although GPR40 and GPR84 are involved in diverse physiological processes, no evidence has demonstrated the relevance of GPR40 and GPR84 in fibrosis pathways. Using PBI-4050 (3-pentylbenzeneacetic acid sodium salt), a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively, we uncovered an antifibrotic pathway involving these receptors. In experiments using Gpr40- and Gpr84-knockout mice in models of kidney fibrosis (unilateral ureteral obstruction, long-term post-acute ischemic injury, and adenine-induced chronic kidney disease), we found that GPR40 is protective and GPR84 is deleterious in these diseases. Moreover, through binding to GPR40 and GPR84, PBI-4050 significantly attenuated fibrosis in many injury contexts, as evidenced by the antifibrotic activity observed in kidney, liver, heart, lung, pancreas, and skin fibrosis models. Therefore, GPR40 and GPR84 may represent promising molecular targets in fibrosis pathways. We conclude that PBI-4050 is a first-in-class compound that may be effective for managing inflammatory and fibrosis-related diseases

Leave a Comment

Your email address will not be published. Required fields are marked *